Clinical Trial

A Study of QLM2011 in Subjects With Advanced Solid Tumors

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 17, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial is an open-label, single-center, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors. The purposeaim of this study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of QLM2011 in patients with advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-07.
Trial Details
NCT Number NCT06925659
Lead Sponsor Qilu Pharmaceutical (Hainan) Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 172 participants
Start Date 2025-05
Primary Completion 2026-06 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2025-04-17